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Abstract
Background: Femoral neck fractures in the elderly make up a large proportion of Orthopaedic surgical admissions
each year. Operating on patients with clopidogrel poses a challenge because of the risk of bleeding and the
difficulty deciding the optimal timing of surgery. The aim of this systematic review is to examine the published
evidence to establish a set of guidelines for approaching neck of femur patients who are on clopidogrel.
Methods: All comparative studies with an intervention group and a control group were considered. Data on
patient blood transfusion exposures, units transfused, haemoglobin concentration and drop in haemoglobin
were extracted and pooled using the fixed effects model. Heterogeneity of the intervention effect was
assessed with the I2 statistic.
Results: A total of 4219 studies were identified. After removal of duplicates and after exclusion criteria were
applied, there were 14 studies to be included. All 14 were case series with controls. There was no significant
heterogeneity amongst the studies. Pooled odds ratio for transfusion exposures was 1.24 (95 % confidence
interval 0.91 to 1.71) however this was not statistically significant (p = 0.14). No significant mean differences
were found for other primary outcome measures.
Conclusions: On the available evidence, we recommend that these patients can be managed by normal
protocols with early surgery. Operating early on patients on clopidogrel is safe and does not appear to confer
any clinically significant bleeding risk. As reported in other studies, we believe clopidogrel, if possible, should
not be withheld throughout the perioperative period due to increased risk of cardiovascular events associated
with stopping clopidogrel. Care should be taken intraoperatively to minimise blood loss due to the increased
potential for bleeding.
Trial registration: This systematic review and meta-analysis has been registered on Research Registry on July 16,
2015. The Review Registry Unique Identifying Number is: reviewregistry61.
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Background
Femoral neck fractures in the elderly make up a large
proportion of Orthopaedic surgical admissions each year
and the numbers worldwide are expected to reach 6.26
million cases a year by 2050 [1]. These patients often
present with numerous co-morbidities including coron-
ary artery disease, cerebrovascular disease and peripheral
vascular disease. In fact, recent studies show both a high
incidence of cardiovascular disease among operative hip
fracture patients (63.3 %), as well as a higher risk of
hip fractures among patients with cardiovascular
disease [2–4]. Thus, anticoagulant therapy in patients
presenting with hip fractures is becoming more and
more prevalent.
Increasingly common is the use of clopidogrel, a
thienopyridine derivative, which irreversibly binds to the
platelet receptor adenosine diphosphonate (ADP) and
thus inhibits platelet aggregation and thrombus forma-
tion [5]. The National Institute of Clinical Excellence
(NICE) guidelines recommends clopidogrel for the
prevention and treatment of occlusive vascular events in
patients with recent stroke, myocardial infarction, acute
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coronary syndrome and established peripheral vascular
disease [6]. This includes patients who have undergone
percutaneous coronary intervention and coronary artery
by-pass grafting. The half-life of clopidogrel is 8 h, but the
affected platelets remain irreversibly inactivated and are
replaced by new platelets after 5 to 7 days. Studies have
shown patients to show a complete recovery of platelet
function 7 days after the last clopidogrel dose [7].
Manufacturers and other published guidelines based
on the physiological lifespan of the platelets recommend
stopping clopidogrel at least 5-7 days before undergoing
elective surgery to allow recovery of normal platelet
function and avoid the perioperative risks of increased
bleeding [8–11]. However there is no consensus regard-
ing guidelines for the perioperative management of
clopidogrel in patients with acute femoral neck fractures.
In June 2009 the Scottish Intercollegiate Guidance
Network (SIGN), published a national guideline for the
management of hip fractures in elderly patients and
recommended that surgery should not be delayed in
patients receiving anti-platelet therapy (aspirin, clopidogrel
or dipyridamole) [12].
The difficulty in managing these patients who are on
clopidogrel exists because the increased risk of peri-
operative bleeding and higher risk of spinal haematoma
[13] during the use of regional anaesthesia must be
weighed against the risks of delayed surgery and the
risks associated with the withdrawal of anti-platelet
drugs. The difference between clopidogrel and many
other anticoagulant medications is that there is no
known method of reversing its antithrombotic effects
acutely and the effectiveness of a fresh platelet transfu-
sion in the event of excessive bleeding is controversial.
There are in vitro and clinical studies that suggest plate-
let infusions are an effective method of reversing the
effects of clopidogrel [14–16]. However more recently,
there have been large-scale studies that have been unable
to show any effectiveness of emergency platelet transfu-
sions in patients on antiplatelet therapy [17–19].
The increased bleeding risk of clopidogrel in patients
undergoing surgical procedures has been reported however
there are limited reports to support this in orthopaedic
literature. Most of the studies relate to cardiac surgery and
in these studies clopidogrel has been reported to result in a
four to five times increased risk of haemorrhage-induced
surgical re-exploration and three times increased risk of
blood transfusion post coronary artery bypass graft surgery
[20–22]. Case reports of extensive retroperitoneal hae-
matoma post lumbar sympathetic blockade and cervical
epidural haematoma post epidural injection resulting in
quadriparesis have further highlighted the bleeding risks
associated with clopidogrel [23, 24].
To minimise the risks of perioperative bleeding related
to clopidogrel, surgery can be delayed for at least 5 to 7
days. However the risks of delaying surgery in femoral
neck fracture patients is well documented. Numerous
studies have shown that a surgical delay in femoral neck
fracture patients can lead to significantly poorer patient
outcomes including an increased mortality rate, prolonged
in-hospital stay time and a reduced rate of return to inde-
pendent living [25–29]. Delay to surgery greater than 48 h
has been shown to be independently associated with a
higher mortality rate at 30 days and 1 year [30]. A
prospective observational study of 2660 patients and
found a significant increase in mortality in hip fracture
patients delayed more than 4 days for surgery compared
to those operated without delay (10.7 % vs 8.7 %) [31].
Another important consideration is that of the risk of
withholding clopidogrel in these hip fracture patients
with cardiovascular comorbidities. Studies have shown
that fractures, surgical procedures and trauma induce
both an inflammatory and coagulatory effect [32, 33].
Withholding clopidogrel in hip fracture patients can
potentially induce a rebound effect and cause thrombo-
embolic events whilst in this prothrombotic state. There
are reports of a perioperative incidence of acute coron-
ary syndrome of up to 20.2 % in patients with femoral
neck fractures [34]. In patients who have had coronary
stents inserted, cessation of clopidogrel treatment during
the first year is associated with a 20 % risk of myocardial
infarction and 45 % mortality rate [35]. This risk is of
particular concern to those with drug-eluting stents, for
which dual-antiplatelet therapy is prescribed on an
empirical basis for 3-6 months after implantation, with
life-long aspirin. Studies have shown that patients who
prematurely cease clopidogrel therapy, have a signifi-
cantly increased risk of hospitalisation and mortality
within the first 11 months due to stent thrombosis [36].
In addition, there have also been rising concerns for
patients with drug-eluting stents regarding the risk of
late stent occlusion after cessation of clopidogrel [37].
This difficult balancing act in managing these patients
has resulted in a lack of consensus about the best prac-
tice and safest approach, and this is demonstrated by a
wide variation in policies between different Orthopaedic
departments. A number of published surveys of ortho-
paedic departments across the UK and US have demon-
strated this variation, each of them largely based on
anecdotal evidence [38–41]. One survey of 139 UK
orthopaedic departments published in 2007 revealed 41
% stopped clopidogrel and operated immediately, 19 %
continued clopidogrel and operated immediately, 21 %
stopped clopidogrel for at least 5 days preoperatively
and 19 % had various alternative protocols [38].
The aim of the study was to determine if operating
early on patients with neck of femur fractures who are
on clopidogrel increases the risk of clinically significant
bleeding, reflected in rate of blood transfusions and
Soo et al. BMC Musculoskeletal Disorders  (2016) 17:136 Page 2 of 11
postoperative decreases in haemoglobin concentrations,
when compared to patients who are not on clopidogrel.
A secondary aim was to establish a framework for man-
aging neck of femur patients who are on clopidogrel.
Methods
Search strategy
A comprehensive search was performed using the
following databases: The Cochrane Library (Wiley, to
February 2015), MEDLINE (Ovid, 1946 to February
2015) and EMBASE (Ovid, 1974 to February 2015), and
Google scholar (to February 2015). The following key-
words were used: Anticoagulant”, “Plavix”, “Clopidogrel”,
“Thienopyridine”, “Antiplatelet therapy”, “Hip fractures”,
“Femoral neck fractures”, “Neck of femur fractures”,
“Orthopaedic surgery”, “Surgery”, “Bleeding”, “Blood loss”
(Additional file 1). Additionally all references of the
retrieved articles were also checked for additional relevant
studies. Studies selected were original clinical studies that
addressed the use of clopidogrel in patients undergoing
surgery for neck of femur fractures. All comparative stud-
ies with a treatment group and a control group were
considered. Data limits were set from all journals up to
February 2015. Exclusion criteria were: (1) studies com-
paring non-clopidogrel anticoagulant medication, (2) stud-
ies without neck of femur patients, and (3) studies other
than clinical studies such as reviews, letters, editorials and
expert opinions.
Data extraction
Data were extracted by one of the investigators (first
author) and checked by a second investigator (second
author). The authors were not blind to authorship, jour-
nal of publication, or results of the trials. Extracted data
included assessment of study quality, study design, num-
ber of patients, patient characteristics (age, gender,
fracture), surgical treatment, number of days free of
clopidogrel, and perioperative use of other anticoagu-
lants, and follow-up. Outcome measures were divided
into primary and secondary. Primary outcome measures
included (1) allogeneic and autologous blood transfusion
exposures or average number of units transfused per
patient and (2) a postoperative haemoglobin concen-
tration or a drop in haemoglobin concentration. Sec-
ondary outcome measures were recorded from the
included studies if available: average time to surgery,
length of stay in hospital and postoperative complica-
tions (including haematoma, cardiovascular, cerebro-
vascular, thromboembolic events, death).
Quality appraisal
The quality of the studies was appraised based on a se-
lect number of well described quality appraisal methods
[42–44]. These were: (1) study design- whether the study
met the requirements of our research question, for
example a comparative study with clopidogrel patient
groups and non clopidogrel patient groups; (2) prospect-
ive or retrospective study; (3) study population clearly
specified and defined; (4) homogeneity concerning
patient population- for example patients on clopidogrel
only or patients who are also on aspirin; (5) transparency
of outcome measures and assessment; (6) transparency
of missing data; (7) appropriate data management and
statistics in relation to our research question; (8)
confounding variables assessed, measured and commen-
ted on- for example the concurrent use of aspirin. The
same investigators scored the items and assessed bias,
and any disagreements were resolved by consensus.
Meta-analysis
This was done using the fixed effects model. Heterogeneity
of the intervention effect was assessed with the I2 statistic.
Data analysis was performed using Review Manager 5.1
(The Cochrane Collaboration, 2011).
This systematic review conforms to the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) standards (Additional file 2).
Results
Search results
The literature search identified 4220 possible eligible
studies (Fig. 1) Initial screening of titles and removal of
duplicates left 182 articles remaining. Exclusion criteria
were studies comparing the use of other anticoagulant
medication and surgical procedures not involving treat-
ment of fracture of the femoral neck. The abstracts of
these citations were reviewed and an additional 161 were
rejected. This left 21 articles to be retrieved in full text
Fig. 1 Flow diagram of literature search
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and to be assessed for eligibility. 14 articles were
included in the qualitative synthesis and 7 excluded. Of
the 7 articles excluded: two were review articles [45, 46],
one was a cohort study without a comparison [47], two
were published abstracts from an international meet-
ing and not published peer reviewed articles [48, 49],
and two studies which included no primary outcome
measures (only secondary outcome measure of com-
plications) [50, 51].
Study characteristics
All the reports were from a single centre except Chechick
et al. [52] and Nydick et al. [53] who enrolled study
patients from two orthopaedic trauma centres, and Feely
et al. [54] which was a population based study using the
records of health care providers in the Olmsted County,
Minnesota (as part of the Rochester Epidemiology Pro-
ject). The earliest study was from 2007, and the most
recent was from 2014. The total number of patients across
all the studies was 2938. The largest population size was
1225 patients, with 30 in the clopidogrel group (CG) and
1195 in the control or non-clopidogrel group (NCG)
(Wordsworth et al. [55]). The study characteristics of all
the included studies are summarized in table 1.
All of the studies were comparative cohort studies,
ten of which compared neck of femur fracture patients
who were on clopidogrel (CG) with control patients
who had never been on clopidogrel (NCG). Five studies
performed comparative analysis of clopidogrel patients
who had surgery within 5 or 7 days (CG < 5 or <7), and
those who were on clopidogrel but had their surgery
delayed for a minimum of 5 or 7 days (CG > 5 or >7)
[56–60]. One study included both types of comparative
analysis [57].
Primary outcomes
Thirteen out of the fourteen studies included either the
number of transfusion exposures or the average number
of units transfused per patient. Twelve out of fourteen
studies described postoperative haemoglobin or a drop
in haemoglobin. The primary outcomes for the studies
are summarized in the table 2.
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et al. 2013 [60]
Case-control
(Retrospective)
47 (<5 days) 24
(>5 days) 23
No significant difference in outcomes betweenCG < 5 and
CG >5CG > 5 had 2 pre-op cardiac complications and 4
patients died from cardiac complications.CG < 5 had 2
patients die from cardiac complications.
Wordsworth
et al. 2013 [55]
Case-control
(Prospective)
1225 30 1195 No significant difference in outcomes between CG and NCG
Manaqibwala
et al. 2014 [64]
Case-control
(Retrospective)
162 15 147 No significant difference in time to outcomes between CG
and NCGSignificantly lower preop Hb and higher ASA in CG
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Harty et al 2007 [68] 9.8 9.6 0.68
Johansen et al 2008 [56] 1.0 0.2 - 3.7 2.4 0.01
Sim and Gonski 2009
[57]CG vs NG
4/21 37/114 0.30 10.7 (1.7) 10.3 (1.6) 0.44
Sim and Gonski 2009
[57]CG <5 vs CG >5
2/16 2/5 >0.05 10.3 10.9 >0.05
Cox et al 2009 [58] 0.9 0.2 3.1 1.8 <0.05
Nydick et al 2010 [53] 16/23 12/27 0.13 1.50 1.77 0.54
Chechik et al 2011 [52] 1.38 (0.98) 1.09 (1.38) >0.05
Wallace et al 2012 [63] 29/52 18/58 0.01 9 (1.9) 9.5 (1.7) 0.41
Collinge et al 2012 [62] 22/40 342/619 0.89 1.4 (1.7) 1.5 (2.3) 0.50 10.1 (1.2) 10.2 (1.2) 0.52
Chechik et al 2012 [59] 6/30 9/30 0.38 0.37 0.47 0.64 2.6 1.8 0.19
Hossain et al 2013 [61] 4/50 2/52 0.37 2.0 (0) 2.5 (0.7) 0.16 10.8 (1.5) 11.1 (1.5) 0.37
Feely et al 2013 [54] 9/40 14/80 0.51 2.1 (2.1) 2.1 (3.5) 0.49 9.1 (1.2) 9.0 (1.1) 0.64 3.0 (1.7) 3.5 (1.6) 0.08
Al Khudairy et al 2013 [60] 6/24 8/23 >0.05 0.8 (1.6) 0.7 (1.1) >0.05 1.5 1.1 >0.05
Wordsworth et al 2013 [55] 9/30 309/1195 0.67 0.67 0.55 0.54
Manaqibwala et al 2014 [64] 0.9 (1.1) 0.6 (1.4) 0.23 10.3 (2.2) 11.4 (1.5) 0.07 0.8 (1.0) 0.6 (1.3) 0.32













Most studies presented good preoperative data to
help assess the matching of the two groups. The most
useful of these were patient age and sex, type of frac-
ture and type of surgery, and ASA (American Society
of Anesthesiologists) score. In terms of primary out-
come data comparison, we felt the best guide was the
postoperative Haemoglobin (Hb) or the drop in Hb,
even though this in itself is an indirect measure of
blood loss, influenced by several other patient and
perioperative factors. This was unfortunately poorly
recorded in some studies and often described at
different time points e.g. immediately post op, day 1
post op, day 2 post op, at the point of discharge.
Some studies described the lowest haemoglobin level
during the postoperative period. The ideal point of
time for the Hb level would be immediately postoper-
atively because this would usually be prior to blood
transfusions (Except those given preoperatively or
intraoperatively).
The other primary outcome measure we used was
transfusion exposures and mean total units transfused
per patient. Ten of the studies included data on both
measures. However describing blood loss in terms of
transfusion requirements is difficult due to the variability
in transfusion protocols, reflected by the wide variation
in transfusion rates between studies (from 5.8 % total
exposures as reported by Hossain et al. [61] up to 55.3 %
as reported by Collinge et al. [62]).
Secondary outcomes
Secondary outcome measures were also recorded from the
included studies if available. These were average time to
surgery, length of stay in hospital and postoperative compli-
cations (including haematoma, cardiovascular, cerebrovas-
cular, thromboembolic events and death). The secondary
outcomes are summarised in table 3.
The most consistently reported secondary outcome mea-
sures were time from admission to theatre and mortality



























3.5 (3.2)/0.9 (0.8) <0.001 23.1 (17.7)/22.6 (21.4) 0.92 1/1 1/2
Cox et al
2009 [58]
25/30 <0.05 2/0 2/1
Nydick et al
2010 [53]
1.88/1.68 0.64 0/0 1/1 0/1 0.35
Chechik et al
2011 [52]





6.0 (3.4)/5.6 (4.0) 0.61 0/10 0.89 0/9 0.95 3/39 0.23
Chechik et al
2012 [59]
1.7 (1)/7.5 (2.71) <0.001 11.1 (4.8)/17.7 (7.2) 0.0002 1/3 0.50 3/5 0.49 0/2 0.16
Hossain et al
2013 [61]
17.3 (13.3)/20.5 (16.6) 0.28 3/1 0.36 0/0
Feely et al
2013 [54]
1.1 (0.7)/1.3 (1.3) 0.77 2/3 1.00 10/10 0.28 11/23 0.23
Al Khudairy
et al 2013 [60]
4.2 (1)/8 (1) <0.05 21.2 (11.9)/28.7 (16.4) >0.05 0/0 0/2 2/4
Wordsworth
et al 2013 [55]
1.2/1.2 0.91 0/2 1.00 2/74 0.71
Manaqibwala
et al 2014 [64]
2.3 (2.0)/1.9 (2.9) 0.25 10.6 (5.6)/7.4 (7.6) 0.04 1/2 0.25 2/6 1.00 1/6 0.24
Values are mean (Standard Deviation)
aHaemorrhage includes serious bleeding such as GI Bleed or Intracranial Haemorrhage
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rate, with eleven out of the fourteen studies having reported
both of these. Average time to theatre was a good outcome
measure to help assess the effect of time to surgery on
primary outcomes, and also to help assess for confounding.
Five studies [56–60] specifically grouped their study
patients according to time to surgery as their primary aim.
Out of the remaining nine studies that did not separate the
groups in terms of time to surgery, seven of them had a
standard protocol of operating on all patients (including
the patients on clopidogrel) as soon as possible without
delay. This helps reduce the possible confounding factor of
trying to compare the Clopidogrel group and control group
with different times from admission to theatre.
Other complications and length of hospital stay were
less consistently reported. Average length of hospital stay
showed a wide variation, most likely reflecting the differ-
ences in hospital protocols or health care systems in
different regions and countries.
Meta-analysis
Meta-analysis was performed on all primary outcome
measures. Forest plots are presented for each measure
(Figs. 2, 3, 4 and 5). The forest plot for transfusion expo-
sures (TE) (Fig. 2) shows the Odds Ratio (OR) for the
relevant studies and we found no evidence of signifi-
cant heterogeneity between the trials (Heterogeneity:
Chi2 = 12.22, df = 8 (P = 0.14); I2 = 35 %). The pooled OR
for the nine studies that reported TE was 1.24 (95 % confi-
dence interval 0.91 to 1.71) with weighting towards in-
creased transfusion exposures in the control group
however this was not statistically significant (p = 0.18).
The forest plots for the remaining three primary out-
come measures, total units transfused per patient (TUT),
post-operative haemoglobin (POH) and drop in haemo-
globin (DH) (Figs. 3, 4 and 5) show minimal mean differ-
ences between clopidogrel and control groups. Further,
any significant mean difference was found to be not
statistically significant: TUT mean difference 0.12 (95 %
CI -018 to 0.43, p = 0.44), POH mean difference -0.12
(95 % CI -0.35 to 0.11, p = 0.30), DH mean difference -0.10
(95 % CI -0.51 to 0.31, p = 0.64). No significant heterogen-
eity being found between studies for each outcome.
Discussion
This systematic review and meta-analysis of the 14 com-
parative studies provides evidence that operating early
on neck of femur patients who are on clopidogrel is safe
and poses no increased risk of bleeding when compared
to patients not on clopidogrel.
In review of the literature, there is a paucity of high-
level evidence to guide the perioperative management of
patients with neck of femur fractures who are also on
clopidogrel. Most of the literature is retrospective and
non-randomised, and this leads to weak conclusions.
Out of all the literature, only fourteen of the available
studies are comparative, none of which are RCTs, and
only two of which is prospective. Meta-analyses of
observational studies also possess limitations due to the
inherent biases that exist in nonrandomized, unblinded
studies. The difficulty in creating large scale rando-
mised clinical trials lies in the complexity of the patient
with femur fractures and their individual and variable
medical comorbidities.
Search strategy
The electronic search strategy proved to be effective,
generating all 13 of the 14 included studies. Only one of
the included studies was not generated from the elec-
tronic searches, and this was from a reference search of
an included study.
Primary outcomes
The assessment and analysis of the data for the primary
outcome measures was difficult due to the studies
presenting their outcomes in different formats.
Most of the studies (13 out of 14) had good patient
demographic data to assess whether the CG and control
group were similar. The most useful was assessment of
Fig. 2 Meta-analysis of clopidogrel group and non-clopidogrel group: transfusions exposures
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age, ASA score, type of surgery and type of fracture, and
most of the studies had matched groups. Only one study
reported a significant difference in age between the two
groups [63]. As expected most studies showed a signifi-
cantly higher number of either cardiovascular or cere-
brovascular disease comorbidities in the intervention
group, however surprisingly only two studies showed a
significant difference in ASA grade [62, 64]. One study
reported a significantly higher number of premorbid
cerebrovascular accidents and transient ischaemic at-
tacks in CG potentially introducing bias for providing
blood transfusions (doctors may have a lower threshold
to transfuse these patients). Of the four studies reporting
the type of anaesthesia used during surgery, there was no
statistically significant differences between the two groups
[54, 55, 58, 61]. Despite the potential risk of spinal haema-
toma in patients using clopidogrel, no anaesthetic compli-
cations were reported in any of the four studies.
In comparing the primary outcomes between the CG
and the controls, the best guide to assess blood loss and
blood replacement is the postoperative Hb. However this
was poorly recorded in some studies, and it was also re-
ported at different times postoperatively e.g. immediately
post op, 24 h post op, 48 h post op, at point of discharge.
Some also only documented the lowest Hb recorded dur-
ing the postoperative period. Ideally it should be taken at
point of discharge because some patients had blood trans-
fusions after the operation and before discharge.
The drop in Hb was poorly reported but the number
of transfusion exposures and the mean units transfused
per patient were generally well reported.
In the studies that reported on transfusion exposures,
and mean units transfused per patient, most found no sta-
tistically significant difference between the groups. Only
one study showed a significant increase in transfusion
exposures in the CG [63]. In terms of Hb concentrations,
there were two studies that reported a significantly higher
drop in Hb in the CG [56, 58]. One study described a
significant increase in perioperative blood loss (which was
not part of our outcome measures due to rarity and incon-
sistency of reporting), however they found no significant
difference in transfusion rates [52]. Thus there appears to
be good evidence to suggest clopidogrel use does not
increase transfusion rates or have significantly more effect
on Hb falls.
A potential confounding factor in the results may be
the concurrent use of aspirin in these patients. Dual-
antiplatelet therapy is the mainstay of postoperative
management of cardiac stent patients. Aspirin use has
been described in a number of studies to be a risk factor
for increased blood loss and transfusion requirements in
hip fractures and hip fracture surgery [65–67].
Fig. 3 Meta-analysis of clopidogrel group and non-clopidogrel group: total units transfused per patient
Fig. 4 Meta-analysis of clopidogrel group and non-clopidogrel group: postoperative haemoglobin
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In our report 8 out of the 14 studies reported on
aspirin use. Only one of these studies showed a signifi-
cant increase in aspirin use in the CG compared to
controls and this study reported no significant difference
in transfusion rates or Hb concentrations between the
groups [55]. Only one study reported on blood loss in
patients on clopidogrel as well as in patients on clopido-
grel and aspirin combined [52]. Their results showed a
significant increase in perioperative blood loss in both
these groups when compared to patients not on any
antiplatelet therapy, however there was no difference in
transfusion rates or Hb concentrations.
Secondary outcomes
The time to theatre was a well reported in most stud-
ies and it provided data not only comparing CG and
controls but also on the effect of early surgery versus
delayed surgery in patients on clopidogrel. Four stud-
ies assessed the differences in outcomes between early
and delayed surgery in CG patients and none of these
studies found a significant difference in bleeding out-
comes. However three of these studies reported in-
creased complications in the delayed surgery group
such as pulmonary emboli, cardiovascular complica-
tions and decubitus ulcers. The results of these studies
suggests that it is unnecessary to delay surgery for
patients on clopidogrel, and on the contrary, delaying
surgery may in fact pose risks of serious complica-
tions. One of the significant concerns for patients on
clopidogrel is the implications of ceasing the antiplate-
let therapy. It is well reported that discontinuation of
antiplatelet therapy in patients with stents (especially
drug-eluting) significantly increases the risks of cardiac
stent thrombosis and death. In correlation with the results
of our study, which suggest an increase in cardiovascular
complications relating to the with-holding of clopido-
grel prior to surgery, we recommend that patients
with stents should continue clopidogrel or at very
least require special consideration and discussion with
the treating cardiologist about continuing or ceasing
anti-platelet therapy.
Seven studies provided data on length of stay and this
varied widely between studies. This probably represented
differences in health care systems and policies in differ-
ent areas and countries. Four of these studies found that
being on clopidogrel significantly prolongs the length of
stay in hospital but it is important to note that two of
them had significant delays to surgery.
The reporting and statistical analysis of other adverse
outcomes such as haematoma, haemorrhage, cardiovas-
cular episodes and mortality was variable between stud-
ies. There were no significant differences in adverse
outcomes between CG and controls, except in one
study which showed a significantly increased mortality
rate in the CG [68].
This study’s results differ slightly with a recently pub-
lished systematic review and meta-analysis by Doleman
and Moppett [69] which found that in the seven studies
they included in their meta-analysis, there was an overall
increase in the proportion of patients receiving blood
transfusions in the clopidogrel group when compared to
the control group (p = 0.05). This difference is accounted
for by the different studies included in the meta-analyses
(nine studies included in our meta-analysis). However the
authors found no difference in mean units transfused
and stated that the under-powering of the included
studies prevented detection of any differences in post-
operative complications.
Conclusions
The combination of increasing population age, the in-
creasing use of clopidogrel and the increasing number of
hip fracture hospital admissions creates an important
issue and potential management concern for orthopaedic
surgeons. There is a relatively large collection of low-
quality evidence showing operating early on neck of
femur fracture patients on clopidogrel to be safe. How-
ever there is still wide variation in clinical practice and
no consensus on recommendations.
The aim of this paper was to gather the best evidence
available on the effect of clopidogrel on hip fracture
surgery patients. Most of the literature is made up of
Fig. 5 Meta-analysis of clopidogrel group and non-clopidogrel group: drop in haemoglobin
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low quality retrospective non-randomised cohort studies
with small sample sizes. Ultimately, large multi-centred,
adequately powered, well-designed randomised trials are
needed to establish clearer guidelines for the management
of these patients.
On the available evidence, we recommend that these
patients can be managed by normal protocols with early
surgery. Operating early on patients on clopidogrel is safe
and does not appear to confer any clinically significant
bleeding risk. As reported in other studies, we believe
clopidogrel, if possible, should not be withheld throughout
the perioperative period due to an increased risk of
cardiovascular events associated with stopping clopido-
grel. Care should be taken intraoperatively to minimise
blood loss due to the increased potential for bleeding.
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